Hematol Oncol. 2006 Mar;24(1):22-7.

Update on the molecular biology of mantle cell lymphoma.

Bertoni F, Rinaldi A, Zucca E, Cavalli F.

Source

Laboratory of Experimental Oncology and Lymphoma Unit, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.

Abstract

Mantle cell lymphoma (MCL) accounts for 5-10% of non-Hodgkin's lymphomas and it bears the worst prognosis among B cell lymphomas. Even more than in the other lymphomas, new insights in MCL biology are needed. In this review we will discuss the most recent published data. Immunoglobulin sequencing data suggest that the MCL cell of origin is a mature B cell which might have undergone an extra-follicular T-cell independent antigen maturation. The main aberrations that affect cell cycle and DNA repair pathways in MCL are summarized, also discussing the need of the t(11;14)(q13;q32) to make diagnosis of MCL. After the gene expression studies of the last years, now the research focus has moved towards the new opportunities provided by arrayCGH technique for gene discovery and for identification of therapeutic targets. Examples of genes identified because deleted or amplified at DNA level and that might be relevant for MCL pathogenesis are presented.

PMID:: 16402392; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms

Publication Types

MeSH Terms

LinkOut - more resources

Full Text Sources

Medical

Supplemental Content

Save items

Related citations in PubMed

Review Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. [J Clin Oncol. 2005]
Review Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways.
Fernàndez V, Hartmann E, Ott G, Campo E, Rosenwald A. J Clin Oncol. 2005 Sep 10; 23(26):6364-9.
Promoter methylation of PARG1, a novel candidate tumor suppressor gene in mantle-cell lymphomas. [Haematologica. 2007]
Promoter methylation of PARG1, a novel candidate tumor suppressor gene in mantle-cell lymphomas.
Ripperger T, von Neuhoff N, Kamphues K, Emura M, Lehmann U, Tauscher M, Schraders M, Groenen P, Skawran B, Rudolph C, et al. Haematologica. 2007 Apr; 92(4):460-8.
Malignant hematopoietic cell lines: in vitro models for the study of mantle cell lymphoma. [Leuk Res. 2002]
Malignant hematopoietic cell lines: in vitro models for the study of mantle cell lymphoma.
Drexler HG, MacLeod RA. Leuk Res. 2002 Sep; 26(9):781-7.
The utility of interphase fluorescence in situ hybridization for the detection of the translocation t(11;14)(q13;q32) in the diagnosis of mantle cell lymphoma on fine-needle aspiration specimens. [Cancer. 2005]
The utility of interphase fluorescence in situ hybridization for the detection of the translocation t(11;14)(q13;q32) in the diagnosis of mantle cell lymphoma on fine-needle aspiration specimens.
Caraway NP, Gu J, Lin P, Romaguera JE, Glassman A, Katz R. Cancer. 2005 Apr 25; 105(2):110-8.
Review Mantle cell lymphoma. [Curr Opin Hematol. 2004]
Review Mantle cell lymphoma.
Bertoni F, Zucca E, Cavalli F. Curr Opin Hematol. 2004 Nov; 11(6):411-8.

See reviews... See all...

Cited by 5 PubMed Central articles

Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. [J Clin Oncol. 2009]
Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909.
Damon LE, Johnson JL, Niedzwiecki D, Cheson BD, Hurd DD, Bartlett NL, Lacasce AS, Blum KA, Byrd JC, Kelly M, et al. J Clin Oncol. 2009 Dec 20; 27(36):6101-8. Epub 2009 Nov 16.
Co-treatment with heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and vorinostat: a highly active combination against human mantle cell lymphoma (MCL) cells. [Cancer Biol Ther. 2009]
Co-treatment with heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and vorinostat: a highly active combination against human mantle cell lymphoma (MCL) cells.
Rao R, Lee P, Fiskus W, Yang Y, Joshi R, Wang Y, Buckley K, Balusu R, Chen J, Koul S, et al. Cancer Biol Ther. 2009 Jul; 8(13):1273-80.
Review Nuclear cyclin D1: an oncogenic driver in human cancer. [J Cell Physiol. 2009]
Review Nuclear cyclin D1: an oncogenic driver in human cancer.
Kim JK, Diehl JA. J Cell Physiol. 2009 Aug; 220(2):292-6.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Update on the molecular biology of mantle cell lymphoma.
Update on the molecular biology of mantle cell lymphoma.
Hematol Oncol. 2006 Mar ;24(1):22-7.

PubMed
Racial/ethnic group differences in treatment decision-making and treatment recei...
Racial/ethnic group differences in treatment decision-making and treatment received among older breast carcinoma patients.
Cancer. 2006 Feb 15 ;106(4):957-65.

PubMed
The role of biofilm infection in urology.
The role of biofilm infection in urology.
World J Urol. 2006 Feb ;24(1):13-20. Epub 2006 Jan 10 .

PubMed
Exercise in the treatment of obesity.
Exercise in the treatment of obesity.
J Fla Med Assoc. 1992 Jun ;79(6):400-2.

PubMed
Further evidence for the association between G72/G30 genes and schizophrenia in ...
Further evidence for the association between G72/G30 genes and schizophrenia in two ethnically distinct populations.
Mol Psychiatry. 2006 May ;11(5):479-87.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: